1. Home
  2. TKC vs TGTX Comparison

TKC vs TGTX Comparison

Compare TKC & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turkcell Iletisim Hizmetleri AS

TKC

Turkcell Iletisim Hizmetleri AS

HOLD

Current Price

$6.46

Market Cap

5.7B

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$35.31

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TKC
TGTX
Founded
1993
1993
Country
Turkey
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
4.9B
IPO Year
2001
2008

Fundamental Metrics

Financial Performance
Metric
TKC
TGTX
Price
$6.46
$35.31
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$49.80
AVG Volume (30 Days)
929.7K
1.7M
Earning Date
05-08-2026
05-04-2026
Dividend Yield
2.47%
N/A
EPS Growth
N/A
1746.67
EPS
N/A
2.77
Revenue
N/A
$2,785,000.00
Revenue This Year
$31.20
$49.08
Revenue Next Year
$24.27
$26.69
P/E Ratio
$26.98
$13.22
Revenue Growth
N/A
N/A
52 Week Low
$5.35
$25.37
52 Week High
$7.18
$46.48

Technical Indicators

Market Signals
Indicator
TKC
TGTX
Relative Strength Index (RSI) 56.01 55.50
Support Level $6.44 $34.37
Resistance Level $6.68 $35.33
Average True Range (ATR) 0.11 1.23
MACD 0.01 0.02
Stochastic Oscillator 54.17 36.56

Price Performance

Historical Comparison
TKC
TGTX

About TKC Turkcell Iletisim Hizmetleri AS

Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes high-quality mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Turkcell International, and Techfin. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: